Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.

GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

(Reuters) - European shares were flat in early trade on Wednesday, as gains led by healthcare stocks following drugmaker Novo ...

GSK plans to buy back £2 billion (S$3.4 billion) of shares as it raised its long-term growth outlook on optimism around its ...

CORE EARNINGS PER SHARE FORECAST: Fourth-quarter core earnings per share is expected to fall to 20.6 pounds from 28.9 pounds the year earlier, according to Visible Alpha. Shares in GSK are 3.6% up ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...

She was previously the supplier's head of commercial excellence for Europe, Middle East, Africa & Latin America ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

The decline in Hindustan Unilever shares this year has helped improve its multiples. The stock is currently trading at 46 times its forward earnings, below its five-year average of about 54 times ...